Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities
Author(s) -
Manuel Hayn,
Maximilian Hirschenberger,
Lennart Koepke,
Rayhane Nchioua,
Jan Hendrik Straub,
Susanne Klute,
Victoria Hunszinger,
Fabian Zech,
Caterina Prelli Bozzo,
Wasim Aftab,
Maria H Christensen,
Carina Conzelmann,
Janis A. Müller,
Smitha Srinivasachar Badarinarayan,
Christina M. Stürzel,
Ignasi Forné,
Steffen Stenger,
KarlKlaus Conzelmann,
Jan Münch,
Florian I. Schmidt,
Daniel Sauter,
Axel Imhof,
Frank Kirchhoff,
Konstantin M. J. Sparrer
Publication year - 2021
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2021.109126
Subject(s) - innate immune system , biology , interferon , immune system , autophagy , interferon type i , severe acute respiratory syndrome , immunology , receptor , virology , coronavirus , microbiology and biotechnology , covid-19 , genetics , disease , medicine , apoptosis , infectious disease (medical specialty) , pathology
SARS-CoV-2 evades most innate immune responses, but may still be vulnerable to some. Here, we systematically analyzed the impact of SARS-CoV-2 proteins on interferon (IFN) responses and autophagy. We show that SARS-CoV-2 proteins synergize to counteract antiviral immune responses. For example, Nsp14 targets the type I IFN receptor for lysosomal degradation, ORF3a prevents fusion of autophagosomes and lysosomes, and ORF7a interferes with autophagosome acidification. Most activities are evolutionarily conserved. However, SARS-CoV-2 Nsp15 antagonizes IFN signaling less efficiently than the orthologues of closely-related RaTG13-CoV and SARS-CoV-1. Overall, SARS-CoV-2 proteins counteract autophagy and type I IFN more efficiently than type II or III IFN signaling and infection experiments confirmed potent inhibition by IFN-γ and -λ1. Our results define the repertoire and selected mechanisms of SARS-CoV-2 innate immune antagonists, but also reveal vulnerability to type II and III IFN that may help to develop safe and effective anti-viral approaches.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom